• Industry News
  • Law & Malpractice
  • Coding & Documentation
  • Practice Management
  • Finance
  • Technology
  • Patient Engagement & Communications
  • Billing & Collections
  • Staffing & Salary

‘Split’ Billing for Workers’ Comp

Article

We usually do “split” billing on workers’ compensation patients. We bill the patient’s primary insurance for the medical condition that is not work related - say, hypertension or diabetes - and then bill the same E&M code on the same day for the same amount to the workers’ comp insurance with the work-related diagnosis. We do two complete visit notes. Is that right?

Question: We usually do “split” billing on workers’ compensation patients. We bill the patient’s primary insurance for the medical condition that is not work related - say, hypertension or diabetes - and then bill the same E&M code on the same day for the same amount to the workers’ comp insurance with the work-related diagnosis.

We do two complete visit notes. Is that right?

Answer: It is OK to bill two separate insurance companies, one for workers’ comp issues and one for nonworkers’ comp issues.

It may not be safe to assume that each service merits the same E&M code. Code based on work done.

A single note to document two services is fine. Of course, both services need to be supported. That is, if an auditor from either carrier were to review the record, each should be able to pull out her company’s documentation requirements.

In other words, a key issue here is whether the patient actually is being seen for hypertension or diabetes during the visit and there is a legitimate, related, medically necessary review of systems and medical decision making for that problem.

Related Videos
The importance of vaccination
The fear of inflation and recession
Protecting your practice
Protecting your home, business while on vacation
Protecting your assets during the 100 deadly days
Payment issues on the horizon
The future of Medicare payments
MGMA comments on automation of prior authorizations
The burden of prior authorizations
Strategies for today's markets
© 2024 MJH Life Sciences

All rights reserved.